Search Results
Dr Susana Banerjee on current treatments and the latest advances in ovarian cancer
Interview with Dr Susana Banerjee
Latest updates in low grade serous ovarian cancer treatment and research
The standard of care and progress so far with PARP inhibitors for ovarian cancer
Drug combination shows promise in treatment-resistant advanced ovarian cancer
SOLO-1: practice changing results for advanced ovarian cancer
SOLO-1: Olaparib or placebo for patients with newly diagnosed BRCA-mutated advanced ovarian cancer
PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023
Gynecologic Oncology at ESMO Congress 2021: RAF/MEK and FAK inhibitor Phase I Study
Introductory Remarks - Susana Banerjee, London
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Ovarian Cancer: Current and Novel Treatment Strategies